No Data
No Data
Insider Purchases Worth US$5.52m See Losses As BriaCell Therapeutics Market Value Drops To CA$40m
BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures
BriaCell Therapeutics Reports Quarterly Financial Loss
10-Q: Q1 2025 Earnings Report
Briacell Therapeutics Highlights The Infiltration Of Cancer Fighting Immune Cells Into Tumors, Using CD8 ImmunoPET Imaging Technology, In Its Poster Presentation At 2024 San Antonio Breast Cancer Symposium
BriaCell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of a $5.5 Million Public Offering of 7.4 Million Shares at $0.75 per Share.